发布求助
文献互助 智能选刊 最新文献

Current Hematologic Malignancy Reports最新文献

筛选
英文 中文
Advances in Novel Systemic Therapies for the Management of Cutaneous T Cell Lymphoma (CTCL).
IF 2.7 3区 医学
Current Hematologic Malignancy Reports Pub Date : 2025-01-13 DOI: 10.1007/s11899-024-00746-7
Katherine B Case, Pamela B Allen
{"title":"Advances in Novel Systemic Therapies for the Management of Cutaneous T Cell Lymphoma (CTCL).","authors":"Katherine B Case, Pamela B Allen","doi":"10.1007/s11899-024-00746-7","DOIUrl":"https://doi.org/10.1007/s11899-024-00746-7","url":null,"abstract":"<p><strong>Purpose of review: </strong>Cutaneous T cell lymphomas (CTCLs) are comprised of a heterogenous group of non-Hodgkin lymphomas that can be difficult to treat and are often refractory to standard therapies. Mycosis fungoides (MF) and Sezary syndrome (SS) are the most common subtypes, accounting for the majority of CTCLs. There is no standard of care, and no treatments are curative. In this review, we summarize the promising, recently reported data describing novel systemic agents for the management of MF/SS.</p><p><strong>Recent findings: </strong>Clinical trials are currently exploring a number of agents, including novel chemotherapies, antibodies and antibody drug conjugates (ADCs), immunotherapy, and cellular therapies. These promising novel agents may expand the treatment landscape for MF/SS.</p>","PeriodicalId":10852,"journal":{"name":"Current Hematologic Malignancy Reports","volume":"20 1","pages":"5"},"PeriodicalIF":2.7,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142969857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mutant Calreticulin in MPN: Mechanistic Insights and Therapeutic Implications.
IF 2.7 3区 医学
Current Hematologic Malignancy Reports Pub Date : 2025-01-08 DOI: 10.1007/s11899-024-00749-4
Mifra Faiz, Merle Riedemann, Jonas S Jutzi, Ann Mullally
{"title":"Mutant Calreticulin in MPN: Mechanistic Insights and Therapeutic Implications.","authors":"Mifra Faiz, Merle Riedemann, Jonas S Jutzi, Ann Mullally","doi":"10.1007/s11899-024-00749-4","DOIUrl":"10.1007/s11899-024-00749-4","url":null,"abstract":"<p><strong>Purpose of review: </strong>More than a decade following the discovery of Calreticulin (CALR) mutations as drivers of myeloproliferative neoplasms (MPN), advances in the understanding of CALR-mutant MPN continue to emerge. Here, we summarize recent advances in mehanistic understanding and in targeted therapies for CALR-mutant MPN.</p><p><strong>Recent findings: </strong>Structural insights revealed that the mutant CALR-MPL complex is a tetramer and the mutant CALR C-terminus is exposed on the cell surface. Targeting mutant CALR utilizing antibodies is the leading therapeutic approach, while mutant CALR-directed vaccines are also in early clinical trials. Additionally, chimeric antigen receptor (CAR) T-cells directed against mutant CALR are under evaluation in preclinical models. Approaches addressing the cellular effects of mutant CALR beyond MPL-JAK-STAT activation, such as targeting the unfolded protein response, proteasome, and N-glycosylation pathways, have been tested in preclinical models. In CALR-mutant MPN, the path from discovery to mechanistic understanding to direct therapeutic targeting has advanced rapidly. The longer-term goal remains clonally-selective therapies that modify the disease course in patients.</p>","PeriodicalId":10852,"journal":{"name":"Current Hematologic Malignancy Reports","volume":"20 1","pages":"4"},"PeriodicalIF":2.7,"publicationDate":"2025-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142946111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Navigating the Economic Burden of Multiple Myeloma: Insights into Cost-effectiveness of CAR-T and Bispecific Antibody Therapies.
IF 2.7 3区 医学
Current Hematologic Malignancy Reports Pub Date : 2025-01-04 DOI: 10.1007/s11899-024-00748-5
Praneeth Reddy Keesari, Diana Samuels, Charan Thej Reddy Vegivinti, Yashwitha Sai Pulakurthi, Revathi Kudithi, Meekoo Dhar, Murali Janakiram
{"title":"Navigating the Economic Burden of Multiple Myeloma: Insights into Cost-effectiveness of CAR-T and Bispecific Antibody Therapies.","authors":"Praneeth Reddy Keesari, Diana Samuels, Charan Thej Reddy Vegivinti, Yashwitha Sai Pulakurthi, Revathi Kudithi, Meekoo Dhar, Murali Janakiram","doi":"10.1007/s11899-024-00748-5","DOIUrl":"10.1007/s11899-024-00748-5","url":null,"abstract":"<p><strong>Purpose of review: </strong>Multiple myeloma is a chronic malignancy and with evolving treatment options, understanding the economic burden and cost-effectiveness of therapies is crucial for clinicians and researchers.</p><p><strong>Recent findings: </strong>In this, we review the recent approval of Bispecific antibodies and CAR-T for myeloma and their cost implications, including direct and indirect costs. We compare this to current regimens and provide cost comparisons in this review. We conclude that the use of more effective therapies such as CAR-T in earlier lines of therapies may be more cost-effective depending on the country and model used. Further studies are essential to better understand the cost-effectiveness of bispecific antibodies including head-to-head comparisons to CAR-T therapy.</p>","PeriodicalId":10852,"journal":{"name":"Current Hematologic Malignancy Reports","volume":"20 1","pages":"3"},"PeriodicalIF":2.7,"publicationDate":"2025-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142926796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Monoclonal Gammopathy-Associated Neuropathy.
IF 2.7 3区 医学
Current Hematologic Malignancy Reports Pub Date : 2024-12-16 DOI: 10.1007/s11899-024-00745-8
Shayna Sarosiek, Christopher T Doughty, Jorge J Castillo
{"title":"Monoclonal Gammopathy-Associated Neuropathy.","authors":"Shayna Sarosiek, Christopher T Doughty, Jorge J Castillo","doi":"10.1007/s11899-024-00745-8","DOIUrl":"10.1007/s11899-024-00745-8","url":null,"abstract":"<p><strong>Purpose of review: </strong>Peripheral neuropathy (PN) is more commonly seen in individuals with monoclonal gammopathies, especially in patients with an IgM monoclonal gammopathy or Waldenström macroglobulinemia.</p><p><strong>Recent findings: </strong>There are multiple potential ways that the paraprotein may result in peripheral neuropathy. The diagnosis and management of monoclonal gammopathy-associated PN are challenging and necessitate a concerted effort between the hematologist/oncologist and the neurologist. This review describes the most common PN syndromes associated with monoclonal gammopathy, such as anti-myelin-associated glycoprotein neuropathy, light chain amyloidosis, cryoglobulinemia, POEMS, CANOMAD, and others. We also review the therapies used to treat these conditions.</p>","PeriodicalId":10852,"journal":{"name":"Current Hematologic Malignancy Reports","volume":"20 1","pages":"2"},"PeriodicalIF":2.7,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142827443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Disparities in Clinical Trial Enrollment- Focus on CAR-T and Bispecific Antibody Therapies.
IF 2.7 3区 医学
Current Hematologic Malignancy Reports Pub Date : 2024-12-04 DOI: 10.1007/s11899-024-00747-6
Nadia Islam, Laura Budvytyte, Nandita Khera, Talal Hilal
{"title":"Disparities in Clinical Trial Enrollment- Focus on CAR-T and Bispecific Antibody Therapies.","authors":"Nadia Islam, Laura Budvytyte, Nandita Khera, Talal Hilal","doi":"10.1007/s11899-024-00747-6","DOIUrl":"10.1007/s11899-024-00747-6","url":null,"abstract":"<p><strong>Purpose of review: </strong>Recent studies show that unresolved disparities hinder enrollment to clinical trials, equitable distribution of treatments, and impact the generalizability of trials, compromising health outcomes across different populations. This review aims to examine the persistent disparities noted in clinical trial enrollment, with particular focus on lymphoid malignancies, CAR-T cell and bispecific antibody therapies.</p><p><strong>Recent findings: </strong>Targeted interventions can enhance recruitment of underrepresented groups in clinical trials and address the complex barriers hindering participation, which are essential for achieving healthcare access equity and treatment outcomes. Improvement must be multifaceted, addressing socioeconomic, geographic, and biologic factors contributing to underrepresentation. This includes more lenient eligibility criteria, improving outreach and education, as well as using technology to diversify trial participation.</p>","PeriodicalId":10852,"journal":{"name":"Current Hematologic Malignancy Reports","volume":"20 1","pages":"1"},"PeriodicalIF":2.7,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11618314/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142767046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pulmonary, Hepatic, and Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Telomere Biology Disorders. 端粒生物学紊乱患者的肺、肝和异体造血干细胞移植。
IF 2.7 3区 医学
Current Hematologic Malignancy Reports Pub Date : 2024-12-01 Epub Date: 2024-02-05 DOI: 10.1007/s11899-024-00724-z
Kelly M Pennington, Douglas Simonetto, Timucin Taner, Abhishek A Mangaonkar
{"title":"Pulmonary, Hepatic, and Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Telomere Biology Disorders.","authors":"Kelly M Pennington, Douglas Simonetto, Timucin Taner, Abhishek A Mangaonkar","doi":"10.1007/s11899-024-00724-z","DOIUrl":"10.1007/s11899-024-00724-z","url":null,"abstract":"<p><strong>Purpose of the review: </strong>This study aimed to summarize evidence and provide consensus-based guidelines for management of transplantation in patients with telomere biology disorders (TBD). Specifically, this review focuses on clinical management of lung, liver, and bone marrow transplantation in TBD patients.</p><p><strong>Recent findings: </strong>TBD patients have specific unique biological vulnerabilities such as T cell immunodeficiency, susceptibility to infections, hypersensitivity to chemotherapy and radiation, and cytopenias. Furthermore, multiple organ involvement at diagnosis makes clinical management especially challenging due to higher degree of organ damage, and stress-induced telomeric crisis. Sequential and combined organ transplants, development of novel radiation and alkylator-free conditioning regimen, and use of novel drugs for graft-versus-host disease prophylaxis are some of the recent updates in the field. Multidisciplinary management is essential to optimize transplant outcomes in patients with TBD. In this review, we provide consensus-based transplant management guidelines for clinical management of transplant in TBD.</p>","PeriodicalId":10852,"journal":{"name":"Current Hematologic Malignancy Reports","volume":" ","pages":"293-299"},"PeriodicalIF":2.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139691449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Contemporary Updates in the Prevention and Treatment of Graft-Versus-Host Disease. 预防和治疗移植物抗宿主病的当代最新进展。
IF 2.7 3区 医学
Current Hematologic Malignancy Reports Pub Date : 2024-12-01 Epub Date: 2024-11-09 DOI: 10.1007/s11899-024-00741-y
Sameem Abedin, Mehdi Hamadani
{"title":"Contemporary Updates in the Prevention and Treatment of Graft-Versus-Host Disease.","authors":"Sameem Abedin, Mehdi Hamadani","doi":"10.1007/s11899-024-00741-y","DOIUrl":"10.1007/s11899-024-00741-y","url":null,"abstract":"<p><strong>Purpose of review: </strong>Graft-versus-host disease (GVHD) is a serious complication after allogeneic HCT. Recently, several pivotal studies have been conducted demonstrating significant improvements in the management of GVHD. Here, we review important trials pertaining to GVHD prevention, acute GVHD treatment, and treatment of steroid refractory acute and chronic GVHD.</p><p><strong>Recent findings: </strong>Clinical trials in preventing GVHD demonstrate lower rates of severe acute GVHD and chronic GVHD with post-transplant cyclophosphamide. For acute GVHD, lower risk acute GVHD appears amenable to steroid-sparing therapies, such as sirolimus and itacitinib. Combinations with novel agents such as itolizumab appear promising for high risk acute GVHD. For steroid-refractory acute GVHD, ruxolitinib should be considered first line therapy. For chronic GVHD requiring therapy beyond steroids, ruxolitinib, belumosudil, and ibrutinib are now available and should be considered. Increasingly, GVHD has become a manageable complication after allogeneic HCT potentially translating to greater success with allogeneic HCT in the future.</p>","PeriodicalId":10852,"journal":{"name":"Current Hematologic Malignancy Reports","volume":"19 6","pages":"246-255"},"PeriodicalIF":2.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142616360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Management of Toxicities Associated with BCMA, GPRC5D, and FcRH5-Targeting Bispecific Antibodies in Multiple Myeloma. 多发性骨髓瘤中与 BCMA、GPRC5D 和 FcRH5 靶向双特异性抗体相关的毒性管理。
IF 2.7 3区 医学
Current Hematologic Malignancy Reports Pub Date : 2024-12-01 Epub Date: 2024-08-15 DOI: 10.1007/s11899-024-00740-z
Darren Pan, Joshua Richter
{"title":"Management of Toxicities Associated with BCMA, GPRC5D, and FcRH5-Targeting Bispecific Antibodies in Multiple Myeloma.","authors":"Darren Pan, Joshua Richter","doi":"10.1007/s11899-024-00740-z","DOIUrl":"10.1007/s11899-024-00740-z","url":null,"abstract":"<p><strong>Purpose of review: </strong>The introduction of bispecific antibodies is one of the most significant recent advances in the treatment of relapsed/refractory multiple myeloma. This review will summarize the management of the toxicities associated with newly approved T cell-engaging bispecific antibodies and those which may be approved in the near future.</p><p><strong>Recent findings: </strong>Numerous trials have shown that bispecific antibodies can be both effective and tolerable when adverse events are properly managed. Cytokine release syndrome and increased infections are observed across all bispecific antibodies. Additional adverse events are target-specific, such as the more severe hypogammaglobulinemia and infections of BCMA bispecific antibodies and the dysgeusia, nail dystrophy, and skin changes of GPRC5D bispecific antibodies. Bispecific antibodies will surely become a mainstay of multiple myeloma therapy given their efficacy and accessibility. Their unique toxicities must be carefully considered and managed to ensure they are utilized safely.</p>","PeriodicalId":10852,"journal":{"name":"Current Hematologic Malignancy Reports","volume":" ","pages":"237-245"},"PeriodicalIF":2.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141981943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Advances in Stem Cell Transplantation for Myelofibrosis. 干细胞移植治疗骨髓纤维化的进展。
IF 2.7 3区 医学
Current Hematologic Malignancy Reports Pub Date : 2024-12-01 Epub Date: 2024-09-06 DOI: 10.1007/s11899-024-00742-x
Akhil Rajendra, Vikas Gupta
{"title":"Advances in Stem Cell Transplantation for Myelofibrosis.","authors":"Akhil Rajendra, Vikas Gupta","doi":"10.1007/s11899-024-00742-x","DOIUrl":"10.1007/s11899-024-00742-x","url":null,"abstract":"<p><strong>Purpose of review: </strong>Allogeneic hematopoietic cell transplantation is the only potentially curative treatment for myelofibrosis. This review discusses issues not well-covered by existing guidelines: timing of transplant, pre-transplant spleen management and alternative donors; providing our approach to these situations.</p><p><strong>Recent findings: </strong>Research continues to allow better identification, by better risk stratification and advances in understanding likelihood of durable JAKi response, which patients are likely to derive benefit from upfront transplant versus those for whom delayed transplant may be more appropriate. Several options of JAKi therapy provide a non-surgical option for pre-HCT splenomegaly management, allowing some patients to avoid risks associated with splenectomy. Recent years have also seen a sharp spike in haploidentical donor transplants, along with narrowing of the gap in outcomes between donor types. Continuous enrollment in prospective studies or well-designed registries is required to generate the high-quality data needed to develop better decision tools for these scenarios.</p>","PeriodicalId":10852,"journal":{"name":"Current Hematologic Malignancy Reports","volume":" ","pages":"256-263"},"PeriodicalIF":2.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142139565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Maintenance Therapy Post-Stem Cell Transplantation for Patients with T-Cell Lymphomas. T 细胞淋巴瘤患者干细胞移植后的维持疗法。
IF 2.7 3区 医学
Current Hematologic Malignancy Reports Pub Date : 2024-12-01 Epub Date: 2024-10-19 DOI: 10.1007/s11899-024-00743-w
Zachary Braunstein, Jonathan E Brammer
{"title":"Maintenance Therapy Post-Stem Cell Transplantation for Patients with T-Cell Lymphomas.","authors":"Zachary Braunstein, Jonathan E Brammer","doi":"10.1007/s11899-024-00743-w","DOIUrl":"10.1007/s11899-024-00743-w","url":null,"abstract":"<p><strong>Purpose of review: </strong>Given the poor outcomes for peripheral T-cell lymphomas (PTCL), stem cell transplant (SCT) remains an important therapeutic approach. Post-SCT relapse is common and maintenance therapy post-SCT is increasingly being utilized. Here we review the use of post-SCT maintenance therapy for PTCL patients.</p><p><strong>Recent findings: </strong>Maintenance therapy is increasingly utilized to decrease post-SCT relapse and improve outcomes in PTCL. Ongoing and completed post-SCT maintenance trials utilizing agents such as romidepsin, brentuximab vedotin, duvelisib, and pembrolizumab have shown efficacy in decreasing relapse. Further, additional agents with efficacy in PTCL have emerged that may inform future maintenance approaches. Maintenance therapy is a promising approach to maintain response after SCT in PTCL. While several trials are ongoing to evaluate maintenance therapy in PTCL, current data suggests this may be an effective method to decrease post-SCT relapse.</p>","PeriodicalId":10852,"journal":{"name":"Current Hematologic Malignancy Reports","volume":" ","pages":"276-284"},"PeriodicalIF":2.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11568030/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142460005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信